



This is a repository copy of *Functional assessment of coronary artery disease in patients with severe aortic stenosis: a review*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/221103/>

Version: Accepted Version

---

**Article:**

Yones, E. [orcid.org/0009-0001-9925-227X](https://orcid.org/0009-0001-9925-227X), Gunn, J. [orcid.org/0000-0003-0028-3226](https://orcid.org/0000-0003-0028-3226), Iqbal, J. [orcid.org/0000-0002-9729-7503](https://orcid.org/0000-0002-9729-7503) et al. (1 more author) (2024) Functional assessment of coronary artery disease in patients with severe aortic stenosis: a review. Heart. ISSN 1355-6037

<https://doi.org/10.1136/heartjnl-2024-324802>

---

© 2024 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in Heart is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# Functional assessment of coronary artery disease in patients with severe aortic stenosis: a review.

Eron Yones<sup>1,2</sup>, Julian Gunn<sup>1,2</sup>, Javaid Iqbal<sup>1,2</sup>, Paul D. Morris<sup>1,2</sup>.

<sup>1</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

<sup>2</sup>School of Clinical Medicine and Population Health, University of Sheffield.

Address for Correspondence:

Dr Eron Yones

Specialty Trainee and Research Fellow in Cardiology

Academic Cardiology Office

Cardiology and Cardiothoracic Surgery Directorate,

Sheffield Teaching Hospitals NHS Foundation Trust,

Sheffield S5 7AU

UK

Eron.yones2@nhs.net

**Word Count: 2959**

## **Abstract**

A significant proportion of patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) have concomitant coronary artery disease. The best way to treat these patients is contentious. Conventional assessments of ischaemia such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are not validated in the context of severe aortic stenosis, despite having a Class I European Society of Cardiology indication in patients with isolated coronary disease. A better understanding of how we assess and interpret coronary physiology in these patients is required to optimise treatment pathways. Only one prospective, randomised trial has investigated the routine use of FFR to guide revascularisation in patients undergoing TAVI, and several observational cohort studies have measured changes in hyperaemic and resting indices in patients with severe AS, as well as before and after TAVI. The purpose of this review article is to provide a summary of the current data regarding the functional assessment of CAD in patients with severe AS and highlight the current best practice in this evolving area.

## **Key words**

Aortic valve stenosis, transcatheter aortic valve replacement, coronary artery disease, percutaneous coronary intervention.

## List of acronyms

aCBF	Absolute coronary blood flow
ACTIVATION	Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Implantation
AS	Aortic stenosis
BCIS	British Cardiovascular Intervention Society
CABG	Coronary artery bypass Grafting
CAD	Coronary artery disease
CCS	Canadian cardiovascular society
CFR	Coronary flow reserve
CT	Computed tomography
DAPT	Dual antiplatelet therapy
ESC	European Society of Cardiology
EACTS	European Association for Cardiothoracic Surgery
EAPCI	European Association of Percutaneous Cardiovascular Interventions
FAITAVI	Functional Assessment in TAVI
FFR	Fractional flow reserve
iFR	Instantaneous wave-free ratio
IMR	Index of microcirculatory resistance
LV	Left ventricle
LVEDP	Left ventricular end diastolic pressure
LVH	Left ventricular hypertrophy
MACE	Major adverse cardiovascular events
MBF	Myocardial blood flow
MVR	Microvascular resistance
NICOR	National Institute for Cardiovascular Outcomes Research
NOTION-3	Revascularisation in Patients Undergoing Transcatheter Aortic Valve Implantation
PARTNER	Placement of Aortic Transcatheter Valves
PCI	Percutaneous coronary intervention
SAVR	Surgical aortic valve replacement
TAVI	Transcatheter aortic valve implantation

## **Introduction**

Fibrocalcific aortic stenosis (AS) is the commonest form of valvular heart disease in the western world, associated with considerable morbidity and mortality, especially in the elderly.<sup>(1)</sup> Treatment guidelines for severe AS have been expanded over the last 20 years and transcatheter aortic valve implantation (TAVI) has gained equipoise with the traditional gold-standard treatment with surgical aortic valve replacement (SAVR) in European Society of Cardiology (ESC) and European Association for Cardiothoracic Surgery (EACTS) guidelines.<sup>(2)</sup> In the UK, TAVI numbers have outstripped SAVR in recent years and are projected to increase further.<sup>(3)</sup> Many patients with AS also have coronary artery disease (CAD), but despite this, the assessment and treatment of concomitant CAD remains a contentious issue. This is also important, because percutaneous access to the coronary arteries is more challenging after TAVI due to the valve apparatus obstructing catheter access to the coronary ostia.<sup>(4)</sup> Physiology-guided treatment of isolated CAD is well validated and guideline-based<sup>(5)</sup>; however, patients with severe AS have been excluded from these trials and therefore, do not feature in the guideline documents. The haemodynamic effects of AS upon coronary physiology and blood flow are complex and require elucidation if we are to understand how best to evaluate and manage CAD in this growing cohort of patients.<sup>(6)</sup> This review article aims to provide an overview of the current literature in this field and offer practical guidance on safe best clinical practice.

## **Aortic stenosis and myocardial blood flow**

In health, a series of tightly controlled autoregulatory mechanisms augment myocardial oxygen supply at rest and stress.<sup>(7)</sup> These are primarily driven by changes in proximal coronary perfusion pressure and microvascular resistance (MVR).<sup>(7)</sup> In AS, several pathophysiological mechanisms impair the capacity of the myocardium to meet rising oxygen demand through exhaustion and impairment of its vasodilatory capacity.<sup>(8)</sup> Progressive AS results in high LV afterload and end-diastolic pressure (LVEDP) with adaptive concentric LV hypertrophy (LVH) in order to generate enough contractile force to eject blood through a stenotic valve.<sup>(9)</sup> The hypertrophied myocardium demands more oxygen, creating a supply: demand mismatch at rest. In response, the autoregulatory mechanisms which augment myocardial blood flow (MBF) during stress are up-regulated through vasodilation of intramyocardial arterioles and

capillaries.<sup>(9)</sup> This results in high resting MBF, recruiting near maximal myocardial vasodilatory capacity, resulting in a supply: demand mismatch during times of physical or pharmacological stress.<sup>(9)</sup> The haemodynamic conditions of LVH are further compounded by low proximal perfusion pressure, short diastolic filling time, relative capillary paucity and high extravascular compressive forces, which eventually result in systolic flow reversal and a reversal of the endocardial: epicardial MBF ratio, which in health is around 1.2: 1.<sup>(8)</sup> This reversal leads to subendocardial ischaemia and myocardial fibrosis, exacerbating angina in patients with AS (with or without CAD).<sup>(8)</sup> Furthermore, in response to these high stress conditions, endothelial cells of the microvasculature become activated and release pro-inflammatory cytokines which impair nitric oxide (NO) production.<sup>(10)</sup> Falling NO further impairs the capacity of the microvasculature to dilate in response to stress and contributes to impairment of coronary vasodilatory capacity.<sup>(10)</sup> The net effect of these pathophysiological mechanisms is to create an environment of high resting MBF with exhaustion of vasodilatory capacity and low CFR. Ahn et al provide insights into these dynamics using cardiac-MRI, showing that AS patients experience microvascular dysfunction with ischaemic symptoms despite absence of CAD.<sup>(11)</sup> Vulnerability to ischaemia becomes even more pertinent in the presence of CAD, emphasising the need to understand indices of coronary physiology in this cohort.

### **Coronary artery disease in aortic stenosis**

The PARTNER-1 trial reported a 74.9% prevalence of significant CAD in high risk patients randomised to TAVI (mean age 83.6±6.8), and PARTNER-2 reported a prevalence of 62.5% in an intermediate risk cohort (mean age 81.5±6.7).<sup>(12, 13)</sup> The ESC and EACTS guidance regarding the management of valvular heart disease recommend coronary angiography in patients >40 years old undergoing valvular intervention (Class IC).<sup>(2)</sup> Revascularisation of CAD is recommended based upon >70% diameter stenosis of a “proximal segment” (Class IIaC) and use of fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) is discouraged.<sup>(2)</sup> Coronary artery bypass grafting (CABG) is recommended in patients undergoing SAVR with ≥70% stenosis in a major epicardial vessel (Class IC).<sup>(2)</sup>

### **TAVI and CAD in the UK**

According to a 2021-22 BCIS and NICOR audit, 2.9% of patients undergoing TAVI had elective percutaneous coronary intervention (PCI) during their work-up, a rate which fell from 7% in 2014.<sup>(14)</sup> The likelihood is that treatment of co-existing CAD is becoming less routine, rather than the prevalence of disease reducing. In a typical tertiary centre (Sheffield Teaching Hospitals, UK), the rate of elective PCI during TAVI work-up has also fallen by >50% since 2017. Only patients with significant proximal CAD and angina undergo PCI, usually at the time of TAVI. Patients >80 years old at the same centre do not have planned angiography prior to TAVI unless they have angina. All patients needing TAVI require a planning CT-scan to guide their procedure.<sup>(15)</sup> Although these scans are not designed to investigate CAD, they are contrast enhanced and, in many cases, can be retrospectively gated in order to detect significant, proximal CAD.<sup>(16)</sup> This represents a possible one-stop diagnostic tool which can reduce invasive procedures and TAVI waiting times.

### **TAVI and CAD in the literature**

The recently published NOTION-3 trial randomised 455 patients (mean age 82 years) with severe AS undergoing TAVI with significant CAD (FFR  $\leq 0.8$  or stenosis  $>90\%$ ) to revascularisation with PCI or conservative treatment.<sup>(17)</sup> At a median follow-up of two years, the primary end-point of death and major adverse cardiovascular events (MACE) occurred in 26% in the PCI group compared with 36% in the conservative group (HR 0.71, 95% CI 0.51-0.99,  $P=0.04$ ) and bleeding in 28% and 20%, respectively (HR 1.51, 95% CI 1.03-2.22). The authors demonstrated that, although patients with CAD undergoing TAVI should have individualised revascularisation decisions, in those deemed suitable, PCI with FFR guidance is safe, feasible and may offer survival benefit.<sup>(17)</sup> Patients with recent myocardial infarction and left main stem disease were excluded and symptomatology did not form part of the inclusion or exclusion criteria.

The ACTIVATION trial randomised 235 patients listed for TAVI with CAD and Canadian Cardiovascular Society (CCS) class  $\leq 2$  angina to angiographically guided PCI or medical therapy. The rates of the composite endpoint of all-cause death and re-hospitalisation at one year were 41.5% for PCI vs 44.0% for medical therapy ( $P=0.07$ ).<sup>(18)</sup> The secondary endpoints of major stroke and MACE at 30 days and one year were also similar. Major bleeding events were significantly higher in patients who had PCI, driven by their need for dual antiplatelet

therapy (DAPT). No objective markers of ischaemia were measured, and significant CAD was defined as >70% stenosis in a major epicardial vessel. Patients with left main stem or ostial CAD were excluded from ACTIVATION and represent a vulnerable cohort who may indeed benefit from PCI before TAVI.<sup>(18)</sup> The mean age was 84 years; and it is not clear whether these findings are applicable to increasingly younger patients being offered TAVI. It should also be noted that isolated AS is known to cause angina without discernible CAD<sup>(19)</sup>; therefore, attributing angina to visualised CAD alone in the context of AS may over-represent significant CAD. Furthermore, patients without angina who have CAD may not necessarily need PCI. PCI is a proven treatment for angina, but has not been shown to improve survival in patients with stable or asymptomatic CAD.<sup>(20, 21)</sup>

### **Aortic stenosis and coronary physiology**

The functional assessment of CAD with FFR and iFR in patients without AS improves clinical outcomes with similar economic costs over several years of follow-up.<sup>(22, 23)</sup> The ESC/EACTS valvular heart disease and revascularisation guidelines discourage physiological assessment of CAD in this cohort despite FFR- and iFR-guided revascularisation gaining a Class IA indication in patients with CAD.<sup>(2, 5)</sup> The interplay between myocardial blood flow, microvasculature and the complex haemodynamic environment of AS can theoretically affect conventional measures of ischaemia (figure 1).

### **Aortic Stenosis and Fractional Flow Reserve**

FFR is the ratio of the distal (Pd) to proximal (Pa) coronary pressure, considered over the entire cardiac cycle (usually the average of three cardiac cycles), acquired during stable hyperaemia. In AS, Pa may not accurately reflect the true coronary driving pressure due to high transvalvular gradients and low blood volume draining into the coronary ostia.<sup>(24)</sup> Furthermore, Pd may be artificially high due to high LVEDP, LVH and high extravascular compressive forces affecting distal coronary pressures.<sup>(24)</sup> The capacity of the microvasculature to respond to pharmacological hyperaemia is also theoretically sub-maximal due to impaired vasodilatory capacity.<sup>(11)</sup> As such, physiological conditions required to measure FFR may not be reliably achieved and potentially misleading FFR results may be produced which underestimate lesion significance using standard threshold values ( $\leq 0.80$ )



and may lead to ‘inappropriate’ deferral of significant lesions (figure 1).<sup>(6)</sup> This is borne out by a meta-analysis of a selection of the studies shown in table 1 by Minten et al.<sup>(25)</sup> FFR values were seen to decrease by around  $0.02\pm 0.07$  ( $P=0.004$ ) when the same lesions were interrogated long-term after TAVI. Therefore, a few borderline cases may be reclassified after TAVI, however this does suggest reliability with strongly positive or negative FFR readings. Pesarini et al demonstrated that when measured immediately pre- and post-TAVI, positive FFR measurements ( $\leq 0.80$ ) decreased significantly and negative FFR values ( $>0.80$ ) improved (see table 1).<sup>(26)</sup> Table 1 shows results of a number of studies investigating whether FFR values change post-TAVI in patients with untreated CAD. These are small, observational studies, so conclusions can only be limited, but measuring FFR in patients with AS seems to be safe, well tolerated and is the only index to evidence MACE reduction.<sup>(17)</sup>

Authors	N	Index	Baseline	Immediately Post-TAVI	P-value	Long-term	P-value	Conclusion
<i>Wiegerinck et al 2015</i> <sup>(27)</sup>	27	FFR	0.97±0.05	0.95±0.06	0.042	NA	NA	<i>Reduction acutely.</i>
<i>Pesarini et al 2016</i> <sup>(26)</sup>	54	FFR	0.89±0.10	0.89±0.13	0.73	NA		<i>No change acutely in overall analysis.</i>
<b>Sub-analysis of Pesarini et al 2016</b>			<b>0.92±0.06</b>	<b>0.93±0.07</b>	<b>&lt;0.001</b>	<b><i>Increase acutely when FFR &gt;0.80</i></b>		
<b>Sub-analysis of Pesarini et al 2016</b>			<b>0.71±0.11</b>	<b>0.66±0.14</b>	<b>&lt;0.001</b>	<b><i>Reduction acutely when FFR ≤ 0.80</i></b>		
<i>Ahmad et al 2018</i> <sup>(28)</sup>	30	FFR	0.87±0.08	0.85±0.09	0.008	NA	NA	<i>Reduction acutely</i>
<i>Stoller et al 2018</i> <sup>(29)</sup>	40	FFR	0.90±0.08	0.93±0.08	0.0021	NA	NA	<i>Increase acutely when FFR &gt;0.80</i>
<i>Scarsini et al 2020</i> <sup>(30)</sup>	14	FFR	0.87 (0.85-0.92)	0.88 (0.83-0.92)	0.49	0.88 (0.82-0.92) (mean-14 months)	0.33	<i>No change acutely or long term</i>

<i>Stundl et al 2020</i> <sup>(31)</sup>	12	FFR	0.77±0.04	-	-	0.76±0.08 (mean 6-8 weeks)	0.11	No change medium term
<i>Vendrik et al 2020</i> <sup>(32)</sup>	13	FFR	0.85 (0.76-0.88)	0.79 (0.74-0.83)	<0.001	0.71 (0.65-0.77) (mean-6 months)	<0.001	Reduction acutely and long-term
<i>Sabbah et al 2022</i> <sup>(33)</sup>	40	FFR	0.84 (0.81-0.89)	-	-	0.86 (.78-0.90) (mean-6 months)	0.72	No change long term
<i>Scarsini et al 2023</i> <sup>(34)</sup>	134	FFR	0.9 (0.84-0.94)	0.88 (0.82-0.93)	0.014	NA	NA	Reduction acutely
<i>Sabbah et al 2023</i> <sup>(35)</sup>	34	FFR	0.90 (0.87-0.92)	NA	NA	0.91 (0.87-0.95)	0.39	No change long term

**Table 1.** Summary of measurements of FFR pre- and post-TAVI in the literature.

### Aortic Stenosis and Instantaneous Wave-free Ratio

The iFR is a non-hyperaemic surrogate index of coronary flow, derived from the Pd/Pa ratio measured during the ‘wave-free’ diastolic period when the relationship between coronary pressure and flow is considered to be linear.<sup>(36)</sup> In AS, increased LVEDP and LVH cause compression of intramyocardial vessels during diastole, raising coronary resistance and potentially decreasing iFR values.<sup>(37)</sup> Furthermore, iFR is not dependent upon hyperaemia, but the haemodynamic conditions of severe AS mimic hyperaemia in order to meet high demand conditions, and can result in false positive values.<sup>(37)</sup> However, Yamanaka et al found that iFR may be a more reliable index than FFR in AS patients because it is less influenced by changes in Pa and LV pressure fluctuations seen in AS.<sup>(38)</sup> They observed that, post-TAVI, iFR correlated better with myocardial perfusion imaging, suggesting that iFR may provide a more consistent reflection of coronary physiology in AS.<sup>(38)</sup> In a comparative study by Scarsini et al, iFR was shown to have better stability than FFR in AS patients, with values that were more consistent pre- and post-TAVI.<sup>(39)</sup>

Table 2 demonstrates a number of small observational studies in which iFR values were measured before, acutely post-TAVI and long-term in patients without significant CAD. In all studies, the pre-TAVI iFR value was positive ( $\leq 0.89$ ), corroborating the fact that patients with severe AS are already running at a near maximal hyperaemia, making resting indices of coronary physiology difficult to interpret. In a meta-analysis of the studies in table 2 by Minten et al, the iFR was found to increase non-significantly following TAVI ( $0.016 \pm 0.07$ ,  $P=0.054$ ).<sup>(25)</sup> This suggests initial overestimation of lesion significance with incomplete regression of the contributing haemodynamic factors post-TAVI.

Authors	N	Index	Baseline	Immediately Post-TAVI	P-value	Long-term	P-value	Conclusion
Ahmad et al 2018 <sup>(28)</sup>	30	iFR	0.88 $\pm$ 0.09	0.88 $\pm$ 0.09	0.94	NA	NA	No change
Scarsini et al 2018 <sup>(39)</sup>	66	iFR	0.89 $\pm$ 12	0.89 $\pm$ 12	0.66	NA	NA	No change
Scarsini et al 2020 <sup>(30)</sup>	14	iFR	0.88 (0.85-0.96)	0.90 (0.83-0.93)	0.30	0.91 (0.86-0.97) (mean-14 months)	0.30	No change
Vendrik et al 2020 <sup>(32)</sup>	13	iFR	0.82 (0.80-0.90)	0.83 (0.77-0.88)	0.735	0.83 (0.73-0.90) (mean-6 months)	0.735	No change

**Table 2.** Summary of measurements of iFR pre-and post-TAVI in the literature.

### Aortic Stenosis and Coronary Flow Reserve

Coronary Flow Reserve (CFR) is the ratio of maximal hyperaemic to resting coronary blood flow and is a measure of both epicardial and microvascular function.<sup>(40)</sup> In severe AS, CFR is typically reduced due to limited vasodilatory capacity, resulting from LVH and increased resting MBF.<sup>(41)</sup> Patients with AS have reduced coronary flow during hyperaemia because their hypertrophied myocardium demands greater blood flow than the exhausted microvasculature can supply.<sup>(41)</sup> Impaired CFR reflects microvascular dysfunction associated

with AS, which contributes to angina and ischaemic symptoms even in the absence of CAD.<sup>(41)</sup> Furthermore, high LVEDP in AS patients compresses the coronary microvasculature, limiting the ability to increase flow during stress. This reduced vasodilatory capacity is exacerbated by the hypertrophied myocardium, which demands oxygen but receives inadequate blood flow due to limited CFR.<sup>(42)</sup> Steadman et al demonstrated that patients with AS have significantly reduced CFR, particularly those with LVH, and that CFR often improves post-TAVI as aortic and LV pressures normalise.<sup>(42)</sup> Paolisso et al found that CFR was significantly lower in AS patients due to elevated MVR and reduced vasodilatory reserve.<sup>(9)</sup> After TAVI, there was a marked improvement in CFR, suggesting that TAVI helps restore microvascular function and improves overall myocardial perfusion.<sup>(9)</sup> Table 3 lists the studies measuring CFR improvement post-TAVI. These findings emphasise that CFR is a useful index for understanding the full extent of coronary dysfunction in AS patients and its potential reversibility after valve replacement.

Authors	N	Index	Baseline	Immediately Post	P-value	Long-term	P-value	Conclusion
Camuglia et al 2014 <sup>(43)</sup>	8	CFR	1.53 (1.27-1.8)	1.58	0.41	2.18 (1.88-2.7) (mean-12 months)	<0.01	No change acutely. Increase long-term
Wiegerinck et al 2015 <sup>(27)</sup>	27	CFR	1.9±0.46	2.1±0.65	0.113	NA	NA	No change acutely
Stoller et al 2018 <sup>(29)</sup>	40	CFR	1.9±0.9	2.0±1.0	0.72	NA	NA	No change acutely
Vendrik et al 2020 <sup>(32)</sup>	13	CFR	1.28 (1.1-1.51)	1.65 (1.47-1.85)	<0.001	1.94 (1.69-2.25) (mean-6 months)	<0.001	Increase acutely and long-term
Scarsini et al 2023 <sup>(34)</sup>	13 4	CFR	2.0 (1.43-2.67)	2.12 (1.45-2.80)	0.805	NA	NA	No change acutely

<i>Sabbah et al</i> 2023 (35)	34	CFR	2.5 (1.5-3.3)	NA	NA	3.1 (2.2-5.1) (mean-6 months)	<0.001	Increase long-term
-------------------------------------	----	-----	---------------	----	----	----------------------------------	--------	--------------------

**Table 3.** Summary of measurements of CFR pre- and post-TAVI in the literature.

### Aortic Stenosis and absolute coronary blood flow

In severe AS, resting absolute coronary flow (aCBF) is high due to LVH, increased myocardial oxygen demand and elevated LVEDP.<sup>(9)</sup> Paolisso et al demonstrated that mean resting aCBF in non-diseased LAD of patients with severe AS was significantly higher than in controls (86mL/min vs 67mL/min, P=0.009).<sup>(9)</sup> CFR was lower in the AS group but hyperaemic flows were similar, thus confirming the mechanism for impaired vasodilatory capacity.<sup>(9)</sup> Invasive assessment of aCBF has been measured pre- and post-AV treatment for severe AS by Sabbah et al, who measured hyperaemic aCBF in the LAD using the Rayflow™ catheter with continuous thermodilution in 34 patients with no flow-limiting CAD. They showed no change in hyperaemic aCBF in the LAD pre- and post-treatment with either SAVR or TAVI at six months.<sup>(35)</sup> They did, however, find a significant improvement in CFR (2.5 vs 3.1, P=<0.01), but FFR and MVR did not change.<sup>(35)</sup> The isolated improvement in CFR suggests a reduction in baseline aCBF (which was not measured) or an increase in hyperaemic MBF when regression of LVH is considered.<sup>(35)</sup> In either case, these data cannot guide revascularisation, but are hypothesis-generating.

### Aortic Stenosis and microvascular assessment

Theoretically, after TAVI, a reduction in LVEDP, LV filling pressures and intra-myocardial pressures should result in reduced MVR. The commonest measure of MVR in practice is the index of microcirculatory resistance (IMR). IMR is measured as the mean Pd multiplied by the thermodilution-derived mean transit time of saline during maximal hyperaemia.<sup>(35)</sup> Sabbah et al measured IMR pre- and post-TAVI in 34 patients and demonstrated no change at 6 months (13±8 vs 13±7, P=1.0).<sup>(35)</sup> These results fall in line with studies by Lumley et al<sup>(44)</sup> and Nishi et al<sup>(45)</sup> who found patients with severe AS to have similar MVR and IMR to healthy controls. This may be due to capillary rarefaction making the LV more efficient at extracting oxygen, ameliorating the need for capillary proliferation and higher MVR.<sup>(35)</sup> MVR remains similar and

increased resting myocardial oxygen demand is provided by a reduction in the CFR. The relatively normal IMR measured in these studies suggest that a minimal level of resistance is reached in severe AS which does not fall further, but allows almost maximal recruitment of the capillary bed. Therefore, changes in MBF after treatment of severe AS are not necessarily driven by changes in MVR but through pathophysiological mechanisms of cardiac-coronary coupling already described.<sup>(44)</sup>

### **AS and CT-FFR**

CT-FFR may provide a unique opportunity to assess coronary physiology and TAVI planning in one investigation. Michail et al recruited 42 patients with severe AS to invasive and CT-based FFR assessment.<sup>(46)</sup> Mean invasive FFR was 0.83 and mean CT-FFR was 0.77.<sup>(46)</sup> There was a 76.7% diagnostic accuracy. Although the authors declared the safety and feasibility of CT-FFR in AS, the relatively modest diagnostic accuracy (23.3% of cases were misdiagnosed) does not suggest widespread use is yet applicable. This was a small single-centre study that excluded patients with significant CAD (>90% stenosis or previous revascularisation) and heart failure. Michiels et al measured CT-FFR pre- and post-TAVI or SAVR in 23 patients.<sup>(47)</sup> Although a statistically significant decrease in LV-mass was noted after treatment of severe AS, CT-FFR values remained unchanged. No invasive FFR were measured for validation and no patients with CAD of >30% were included. Therefore, the real-world validity of assessing coronary physiology using CT-FFR remains a question to be answered.

### **Discussion and future directions**

TAVI has revolutionised the treatment of AS, but the physiological assessment of concomitant CAD is experiencing a “catch-up” period. The studies above highlight the complexities associated with coronary physiology in the context of severe AS, and demonstrate the need for robust randomised data. The evidence for the long-term health benefits of physiologically-assessed CAD in the non-valve-diseased population are clear, whereas the evidence for long-term benefits of PCI with or before TAVI, are less definitive.

Although the studies described in tables 1-3 are insightful, it must be noted that mean values cannot represent individual patient level data. Only Stundl et al<sup>(31)</sup> and Pesarini et al<sup>(26)</sup> re-measured FFR if it was  $\leq 0.80$  and the rest only studied patients with FFR values  $> 0.8$ . The

studies in table 2 all demonstrated positive mean iFR values ( $\leq 0.89$ ). In all of these studies, FFR was measured in the same lesions, revealing negative mean values ( $> 0.8$ ). These conflicting findings demonstrate the challenges of interpreting data from heterogeneous study populations, although Minten et al have produced a helpful meta-analysis of these studies.<sup>(25)</sup> Furthermore, not all patients with AS live within an identical physiological environment. Patients with extra-valvular LV failure or low-flow AS phenotype may represent a cohort to which revascularisation guidance based on relatively small trials such as NOTION-3 may not be applicable.

Whilst further randomised data are awaited, best practice guidance is offered by Tarantini et al in a clinical consensus statement from the EAPCI and ESC working group on Cardiovascular Surgery.<sup>(48)</sup> We have suggested a treatment pathway based upon this expert consensus and available data<sup>(17)</sup> to offer a practical guide to the general cardiologist (figure 2).

### **Funding**


PDM was funded by the Wellcome Trust [214567/Z/18/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

This study/research is partly funded by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321\*). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

### **Conflicts of interest**

The authors have no relevant conflicts of interest.


Figures



**Figure 1.** The effects of aortic stenosis and its physiological sequelae upon myocardial blood flow and Pd/Pa measurement. FFR is measured as hyperaemic Pd/Pa, with a cut-off value of  $\leq 0.80$ , as the threshold for physiological significance and intervention. Theoretically, the haemodynamic conditions associated with AS contribute to a lower Pa and an elevated Pd, resulting in a negative FFR measurement and an ‘underestimation’ (in comparison with normal conditions) of coronary stenosis significance, which can result in deferral of PCI, which may be regarded as inappropriate. Pa; mean proximal aortic pressure. Pd; mean distal coronary pressure. FFR; fractional flow reserve. PCI; percutaneous coronary intervention. Created in BioRender. Yones, E. (2024) <https://BioRender.com/p78m825>.



### Suggested treatment pathway for patients with severe AS undergoing TAVI with CAD



**Figure 2.** Suggested treatment pathway for patients with severe AS undergoing TAVI who have CAD at angiography (based on Tarantini et al).<sup>(48)</sup> When angiographically significant CAD is associated with symptoms of angina, recent myocardial infarction or sub-occlusive CAD, it is appropriate to perform PCI prior to TAVI. When there is intermediate CAD and uncertain symptomatology, non-invasive imaging suggestive of ischaemia or clinical suspicion of ischaemia, FFR is recommended as the most reliable measure of physiological significance. Note that FFR may slightly underestimate physiological significance in borderline cases by about +0.02 relative to post TAVI measurements.<sup>(25)</sup> Clearly positive or negative FFR values are likely to be reliable. In cases of angiographically intermediate CAD and absence of symptoms, PCI can be safely deferred; but if future PCI is anticipated, a balloon expanded

intra-annular valve is recommended, associated with easier coronary access post-TAVI. <sup>(49)</sup>

Created in BioRender. Yones, E. (2024) <https://BioRender.com/g85i548>.

## References

1. Pawade TA, Newby DE, Dweck MR. Calcification in Aortic Stenosis: The Skeleton Key. *Journal of the American College of Cardiology*. 2015;66(5):561-77.
2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2021.
3. Transcatheter Aortic Valve Implantation Registry 2024 [Internet]. 2024. Available from: <https://www.nicor.org.uk/publications/ncap/uk-transcatheter-aortic-valve-implantation/2024-8/tavi-final-report-2022-23?layout=default>.
4. Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary Angiography and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. 2018;71(12):1360-78.
5. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *EuroIntervention*. 2019;14(14):1435-534.
6. Sen S, Ahmad Y, Davies J. Assessing coronary disease in patients with severe aortic stenosis: the need for a 'valid' gold standard for validation studies? *EuroIntervention*. 2018;13(13):1499-502.
7. Johnson NP, Gould KL, Bruyne BD. Autoregulation of Coronary Blood Supply in Response to Demand. *Journal of the American College of Cardiology*. 2021;77(18):2335-45.
8. Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021;78(13):1352-71.
9. Paolisso P, Gallinoro E, Vanderheyden M, Esposito G, Bertolone DT, Belmonte M, et al. Absolute coronary flow and microvascular resistance reserve in patients with severe aortic stenosis. *Heart*. 2022;109(1):47-54.
10. Barbato JE, Tzeng E. Nitric oxide and arterial disease. *Journal of Vascular Surgery*. 2004;40(1):187-93.
11. Ahn JH, Kim SM, Park SJ, Jeong DS, Woo MA, Jung SH, et al. Coronary Microvascular Dysfunction as a Mechanism of Angina in Severe AS: Prospective Adenosine-Stress CMR Study. *J Am Coll Cardiol*. 2016;67(12):1412-22.
12. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. 2011;364(23):2187-98.
13. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. 2017;376(14):1321-31.
14. Ludman PF. NICOR BCIS National Audit  
Adult Interventional Procedures 1st April 2021 to 31st March 2022. In: Ludman PF, editor. NICOR BCIS National Audit  
Adult Interventional Procedures 1st April 2021 to 31st March 2022. BCIS2022.
15. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR): An Expert Consensus Document of the Society of Cardiovascular Computed Tomography. *JACC Cardiovasc Imaging*. 2019;12(1):1-24.
16. Androshchuk V, Patterson T, Redwood SR. Management of coronary artery disease in patients with aortic stenosis. *Heart*. 2023;109(4):322-9.
17. Lønborg J, Jabbari R, Sabbah M, Veien KT, Niemelä M, Freeman P, et al. PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation. *New England Journal of Medicine*. 2024;0(0).
18. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION (Percutaneous Coronary intervention prior to transcatheter aortic valve implantation): A Randomized Clinical Trial. *JACC: Cardiovascular Interventions*. 2021;14(18):1965-74.
19. FALLEN EL, ELLIOTT WC, GORLIN R. Mechanisms of Angina in Aortic Stenosis. *Circulation*. 1967;36(4):480-8.

20. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med*. 2020;382(15):1395-407.
21. Bangalore S, Maron DJ, Stone GW, Hochman JS. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. *Circulation*. 2020;142(9):841-57.
22. Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, et al. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). *Circulation*. 2018;137(5):480-7.
23. Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, et al. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *N Engl J Med*. 2017;376(19):1813-23.
24. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Coronary physiology in patients with severe aortic stenosis: Comparison between fractional flow reserve and instantaneous wave-free ratio. *Int J Cardiol*. 2017;243:40-6.
25. Minten L, Bennett J, Otsuki H, Takahashi K, Fearon WF, Dubois C. Differential Effect of Aortic Valve Replacement for Severe Aortic Stenosis on Hyperemic and Resting Epicardial Coronary Pressure Indices. *J Am Heart Assoc*. 2024;13(10):e034401.
26. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, et al. Functional Assessment of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation: Influence of Pressure Overload on the Evaluation of Lesions Severity. *Circ Cardiovasc Interv*. 2016;9(11).
27. Wiegerinck EM, van de Hoef TP, Rolandi MC, Yong Z, van Kesteren F, Koch KT, et al. Impact of Aortic Valve Stenosis on Coronary Hemodynamics and the Instantaneous Effect of Transcatheter Aortic Valve Implantation. *Circ Cardiovasc Interv*. 2015;8(8):e002443.
28. Ahmad Y, Gotberg M, Cook C, Howard JP, Malik I, Mikhail G, et al. Coronary Hemodynamics in Patients With Severe Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement: Implications for Clinical Indices of Coronary Stenosis Severity. *JACC Cardiovasc Interv*. 2018;11(20):2019-31.
29. Stoller M, Gloekler S, Zbinden R, Tueller D, Eberli F, Windecker S, et al. Left ventricular afterload reduction by transcatheter aortic valve implantation in severe aortic stenosis and its prompt effects on comprehensive coronary haemodynamics. *EuroIntervention*. 2018;14(2):166-73.
30. Scarsini R, Lunardi M, Venturi G, Pighi M, Tavella D, Pesarini G, et al. Long-term variations of FFR and iFR after transcatheter aortic valve implantation. *Int J Cardiol*. 2020;317:37-41.
31. Stundl A, Shamekhi J, Bernhardt S, Starke M, Al-Kassou B, Weber M, et al. Fractional flow reserve in patients with coronary artery disease undergoing TAVI: a prospective analysis. *Clin Res Cardiol*. 2020;109(6):746-54.
32. Vendrik J, Ahmad Y, Eftekhari A, Howard JP, Wijntjens GWM, Stegehuis VE, et al. Long-Term Effects of Transcatheter Aortic Valve Implantation on Coronary Hemodynamics in Patients With Concomitant Coronary Artery Disease and Severe Aortic Stenosis. *J Am Heart Assoc*. 2020;9(5):e015133.
33. Sabbah M, Joshi FR, Minkinen M, Holmvang L, Tilsted HH, Pedersen F, et al. Long-Term Changes in Invasive Physiological Pressure Indices of Stenosis Severity Following Transcatheter Aortic Valve Implantation. *Circ Cardiovasc Interv*. 2022;15(1):e011331.
34. Scarsini R, Gallinoro E, Ancona Marco B, Portolan L, Paolisso P, Springhetti P, et al. Characterisation of coronary microvascular dysfunction in patients with severe aortic stenosis undergoing TAVI. *EuroIntervention*. 2023.
35. Sabbah M, Olsen NT, Holmvang L, Tilsted HH, Pedersen F, Joshi FR, et al. Long-term changes in coronary physiology after aortic valve replacement. *EuroIntervention*. 2023;18(14):1156-64.

36. Davies JE, Whinnett ZI, Francis DP, Manisty CH, Aguado-Sierra J, Willson K, et al. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. *Circulation*. 2006;113(14):1768-78.
37. Scarsini R, Pesarini G, Lunardi M, Piccoli A, Zanetti C, Cantone R, et al. Observations from a real-time, iFR-FFR "hybrid approach" in patients with severe aortic stenosis and coronary artery disease undergoing TAVI. *Cardiovasc Revasc Med*. 2018;19(3 Pt B):355-9.
38. Yamanaka F, Shishido K, Ochiai T, Moriyama N, Yamazaki K, Sugitani A, et al. Instantaneous Wave-Free Ratio for the Assessment of Intermediate Coronary Artery Stenosis in Patients With Severe Aortic Valve Stenosis: Comparison With Myocardial Perfusion Scintigraphy. *JACC Cardiovasc Interv*. 2018;11(20):2032-40.
39. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. *EuroIntervention*. 2018;13(13):1512-9.
40. Gould KL, Carabello BA. Why angina in aortic stenosis with normal coronary arteriograms? *Circulation*. 2003;107(25):3121-3.
41. Zelis JM, Tonino PAL, Pijls NHJ, De Bruyne B, Kirkeeide RL, Gould KL, et al. Coronary Microcirculation in Aortic Stenosis: Pathophysiology, Invasive Assessment, and Future Directions. *J Interv Cardiol*. 2020;2020:4603169.
42. Steadman CD, Jerosch-Herold M, Grundy B, Rafelt S, Ng LL, Squire IB, et al. Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. *JACC Cardiovasc Imaging*. 2012;5(2):182-9.
43. Camuglia AC, Syed J, Garg P, Kiaii B, Chu MW, Jones PM, et al. Invasively assessed coronary flow dynamics improve following relief of aortic stenosis with transcatheter aortic valve implantation. *J Am Coll Cardiol*. 2014;63(17):1808-9.
44. Lumley M, Williams R, Asrress KN, Arri S, Briceno N, Ellis H, et al. Coronary Physiology During Exercise and Vasodilation in the Healthy Heart and in Severe Aortic Stenosis. *J Am Coll Cardiol*. 2016;68(7):688-97.
45. Nishi T, Kitahara H, Saito Y, Nishi T, Nakayama T, Fujimoto Y, et al. Invasive assessment of microvascular function in patients with valvular heart disease. *Coronary Artery Disease*. 2017;29:223-9.
46. Michail M, Ihdahid AR, Comella A, Thakur U, Cameron JD, McCormick LM, et al. Feasibility and Validity of Computed Tomography-Derived Fractional Flow Reserve in Patients With Severe Aortic Stenosis: The CAST-FFR Study. *Circ Cardiovasc Interv*. 2021;14(1):e009586.
47. Michiels V, Andreini D, Conte E, Tanaka K, Belsack D, Nijs J, et al. Long term effects of surgical and transcatheter aortic valve replacement on FFRCT in patients with severe aortic valve stenosis. *Int J Cardiovasc Imaging*. 2022;38(2):427-34.
48. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. *EuroIntervention*. 2023;19(1):37-52.
49. Tarantini G, Nai Fovino L, Scotti A, Massussi M, Cardaioli F, Rodinò G, et al. Coronary Access After Transcatheter Aortic Valve Replacement With Commissural Alignment: The ALIGN-ACCESS Study. *Circ Cardiovasc Interv*. 2022;15(2):e011045.

